Unnecessary diagnostic investigations in benign acute childhood myositis: A case series report
Auteur
Neocleous, C.; Spanou, C.; Mpampalis, E.; Xatzigeorgiou, S.; Pavlidou, C.; Poulos, E.; Tzanetis, F.Date
2012Sujet
Résumé
Benign acute childhood myositis (BACM) is a rare, acute, self-limiting muscle disorder, mainly affecting school-aged boys, with an excellent prognosis, requiring no therapeutic intervention. We report a series of seven previously healthy school-aged children with clinical and laboratory findings suggesting BACM where no specific diagnostic investigations were performed. All of the children were hospitalized without any specific therapeutic intervention and were discharged after two or three days free of symptoms, residual impairment or other complication. This report emphasizes that the correct diagnosis of BACM, by considering the characteristic clinical and laboratory findings of this syndrome and by recognizing more severe pathological conditions, which must be excluded from the diagnosis, can prevent unnecessary diagnostic investigations and reassure both parents and patients of the excellent prognosis.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Simulating real-life exposures to uncover possible risks to human health: A proposed consensus for a novel methodological approach
Tsatsakis A.M., Kouretas D., Tzatzarakis M.N., Stivaktakis P., Tsarouhas K., Golokhvast K.S., Rakitskii V.N., Tutelyan V.A., Hernandez A.F., Rezaee R., Chung G., Fenga C., Engin A.B., Neagu M., Arsene A.L., Docea A.O., Gofita E., Calina D., Taitzoglou I., Liesivuori J., Hayes A.W., Gutnikov S., Tsitsimpikou C. (2017)In real life, consumers are exposed to complex mixtures of chemicals via food, water and commercial products consumption. Since risk assessment usually focuses on individual compounds, the current regulatory approach doesn't ... -
Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer
Pagkopoulou E., Simopoulou T., Maragkouli E., Perifanou-Sotiri S., Kotsakis A., Bogdanos D.P. (2020)Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether ... -
IL-35: a new immunomodulator in autoimmune rheumatic diseases
Sakkas L.I., Mavropoulos A., Perricone C., Bogdanos D.P. (2018)IL-35 is a relatively new cytokine that emerges as an important immunomodulator. IL-35 belongs to IL-12 cytokine family that includes IL-12, IL-23, IL-27, and IL-35. These cytokines are heterodimers that share subunits and ...